CN101606906A - 熊去氧胆酸纳米混悬剂及其制备方法 - Google Patents
熊去氧胆酸纳米混悬剂及其制备方法 Download PDFInfo
- Publication number
- CN101606906A CN101606906A CNA2009101582352A CN200910158235A CN101606906A CN 101606906 A CN101606906 A CN 101606906A CN A2009101582352 A CNA2009101582352 A CN A2009101582352A CN 200910158235 A CN200910158235 A CN 200910158235A CN 101606906 A CN101606906 A CN 101606906A
- Authority
- CN
- China
- Prior art keywords
- nano suspension
- ursodeoxycholic acid
- acid nano
- parts
- surfactant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 title claims abstract description 72
- 229960001661 ursodiol Drugs 0.000 title claims abstract description 72
- 239000006070 nanosuspension Substances 0.000 title claims abstract description 57
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 title claims abstract description 43
- 238000002360 preparation method Methods 0.000 title claims abstract description 27
- 239000003814 drug Substances 0.000 claims abstract description 26
- 239000002245 particle Substances 0.000 claims abstract description 21
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229920003081 Povidone K 30 Polymers 0.000 claims abstract description 18
- 239000000843 powder Substances 0.000 claims abstract description 18
- 239000004094 surface-active agent Substances 0.000 claims abstract description 16
- 229940079593 drug Drugs 0.000 claims description 16
- 239000012153 distilled water Substances 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 238000004945 emulsification Methods 0.000 claims description 9
- 239000003085 diluting agent Substances 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 2
- 206010008635 Cholestasis Diseases 0.000 abstract description 3
- 230000007870 cholestasis Effects 0.000 abstract description 3
- 231100000359 cholestasis Toxicity 0.000 abstract description 3
- 208000019425 cirrhosis of liver Diseases 0.000 abstract description 2
- 230000004087 circulation Effects 0.000 description 20
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 14
- 239000004141 Sodium laurylsulphate Substances 0.000 description 14
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 14
- 210000000481 breast Anatomy 0.000 description 13
- 238000000034 method Methods 0.000 description 11
- 238000005516 engineering process Methods 0.000 description 9
- 239000000725 suspension Substances 0.000 description 7
- 239000000523 sample Substances 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 238000001246 colloidal dispersion Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000007716 flux method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000004531 microgranule Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229940023488 pill Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 208000010157 sclerosing cholangitis Diseases 0.000 description 1
- 238000007613 slurry method Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200910158235 CN101606906B (zh) | 2009-07-23 | 2009-07-23 | 熊去氧胆酸纳米混悬剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200910158235 CN101606906B (zh) | 2009-07-23 | 2009-07-23 | 熊去氧胆酸纳米混悬剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101606906A true CN101606906A (zh) | 2009-12-23 |
CN101606906B CN101606906B (zh) | 2012-05-30 |
Family
ID=41480922
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200910158235 Expired - Fee Related CN101606906B (zh) | 2009-07-23 | 2009-07-23 | 熊去氧胆酸纳米混悬剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101606906B (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013057741A2 (en) * | 2011-10-21 | 2013-04-25 | Genovo Development Services Limited | Pharmaceutical compositions of ursodeoxycholic acid |
CN106383234A (zh) * | 2016-08-31 | 2017-02-08 | 上海科华生物工程股份有限公司 | 视黄醇结合蛋白检测试剂的包被方法 |
CN106619163A (zh) * | 2016-12-24 | 2017-05-10 | 青岛科技大学 | 光甘草定纳米混悬剂及其制备方法 |
CN107496928A (zh) * | 2017-09-11 | 2017-12-22 | 石家庄学院 | 一种熊去氧胆酸干混悬剂及其制备方法 |
EP3804702A1 (de) * | 2019-10-10 | 2021-04-14 | Bayer AG | Verfahren zur herstellung einer pharmazeutischen formulierung mit wirkstoff, polymer und tensid |
CN113975233A (zh) * | 2021-10-22 | 2022-01-28 | 北京汇诚益健医药科技有限责任公司 | 一种肠道内稳定的熊去氧胆酸纳米混悬剂的制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101028274A (zh) * | 2006-03-03 | 2007-09-05 | 北京奇源益德药物研究所 | 治疗肝胆疾病的熊去氧胆酸制剂及其制备方法 |
-
2009
- 2009-07-23 CN CN 200910158235 patent/CN101606906B/zh not_active Expired - Fee Related
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013057741A2 (en) * | 2011-10-21 | 2013-04-25 | Genovo Development Services Limited | Pharmaceutical compositions of ursodeoxycholic acid |
WO2013057741A3 (en) * | 2011-10-21 | 2013-06-20 | Genovo Development Services Limited | Pharmaceutical compositions of ursodeoxycholic acid |
CN106383234A (zh) * | 2016-08-31 | 2017-02-08 | 上海科华生物工程股份有限公司 | 视黄醇结合蛋白检测试剂的包被方法 |
CN106383234B (zh) * | 2016-08-31 | 2017-11-24 | 上海科华生物工程股份有限公司 | 视黄醇结合蛋白检测试剂的包被方法 |
CN106619163A (zh) * | 2016-12-24 | 2017-05-10 | 青岛科技大学 | 光甘草定纳米混悬剂及其制备方法 |
CN107496928A (zh) * | 2017-09-11 | 2017-12-22 | 石家庄学院 | 一种熊去氧胆酸干混悬剂及其制备方法 |
CN107496928B (zh) * | 2017-09-11 | 2020-07-14 | 石家庄学院 | 一种熊去氧胆酸干混悬剂及其制备方法 |
EP3804702A1 (de) * | 2019-10-10 | 2021-04-14 | Bayer AG | Verfahren zur herstellung einer pharmazeutischen formulierung mit wirkstoff, polymer und tensid |
WO2021069350A1 (en) * | 2019-10-10 | 2021-04-15 | Bayer Aktiengesellschaft | Process for producing a pharmaceutical formulation comprising active substance, polymer and surfactant |
CN114466650A (zh) * | 2019-10-10 | 2022-05-10 | 拜耳股份有限公司 | 生产包含活性物质、聚合物和表面活性剂的药物制剂的方法 |
CN113975233A (zh) * | 2021-10-22 | 2022-01-28 | 北京汇诚益健医药科技有限责任公司 | 一种肠道内稳定的熊去氧胆酸纳米混悬剂的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101606906B (zh) | 2012-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2595606B1 (en) | Method for preparing microspheres and microspheres produced thereby | |
CN101606906B (zh) | 熊去氧胆酸纳米混悬剂及其制备方法 | |
Wang et al. | Design and optimization of a new self-nanoemulsifying drug delivery system | |
Fagir et al. | Self-microemulsifying systems of Finasteride with enhanced oral bioavailability: multivariate statistical evaluation, characterization, spray-drying and in vivo studies in human volunteers | |
Xu et al. | Formulation and pharmacokinetic evaluation of tetracycline-loaded solid lipid nanoparticles for subcutaneous injection in mice | |
Zhu et al. | Effect of taste masking technology on fast dissolving oral film: dissolution rate and bioavailability | |
CA2439097C (en) | Pharmaceutical compositions | |
Van Ngo et al. | Mechanistic understanding of salt-induced drug encapsulation in nanosuspension via acid-base neutralization as a nanonization platform technology to enhance dissolution rate of pH-dependent poorly water-soluble drugs | |
US7666307B2 (en) | Particle size reduction of bioactive compounds | |
Zou et al. | Andrographolide/phospholipid/cyclodextrin complex-loaded nanoemulsion: preparation, optimization, in vitro and in vivo evaluation | |
Zhang et al. | Nanoemulsion formulation of florfenicol improves bioavailability in pigs | |
Kim et al. | Novel ezetimibe-loaded fibrous microparticles for enhanced solubility and oral bioavailability by electrospray technique | |
Liu et al. | Preparation procedure and pharmacokinetic study of water-in-oil nanoemulsion of Panax notoginseng saponins for improving the oral bioavailability | |
CN101278912A (zh) | 汉防己甲素纳米乳注射剂及其制备方法 | |
Jain et al. | Self-nanoemulsifying formulation for oral delivery of sildenafil: effect on physicochemical attributes and in vivo pharmacokinetics | |
CN108938566A (zh) | 细辛脑自乳化系统 | |
Mbah et al. | Nanovesicle formulation enhances anti-inflammatory property and safe use of piroxicam | |
KR102594716B1 (ko) | 자가나노유화 약물전달시스템을 이용한 니클로사마이드 함유 경구 투여용 조성물 및 이의 제조방법 | |
CN105030732A (zh) | 壳聚糖包封液晶纳米粒所得微球及其制备方法 | |
Pan et al. | Phospholipid complex of ICA and ICA II prepared by wet media milling for improving bioavailability | |
CN101884623B (zh) | 一种左旋多巴甲酯缓释微球组合物及其制备方法 | |
CN108553417A (zh) | 一种蛇床子素自乳化释药系统及其制备方法与用途 | |
CN101035511B (zh) | 形成非层状分散体的组合物 | |
Zhai et al. | An aseptic one-shot bottom-up method to produce progesterone nanocrystals: controlled size and improved bioavailability | |
KR20120034264A (ko) | 막유화법을 이용한 실리마린 경구용 고형제제 조성물 및 그 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
ASS | Succession or assignment of patent right |
Owner name: 302 MILITARY HOSPITAL OF CHINA Free format text: FORMER OWNER: YUAN HAILONG Effective date: 20110402 |
|
C10 | Entry into substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20110402 Address after: 100039 Fengtai District West Fourth Ring Road, Beijing, No. 100 Applicant after: 302 Military of China Address before: 100039 Fengtai District West Fourth Ring Road, Beijing, No. 100 Applicant before: Yuan Hailong |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120530 Termination date: 20200723 |
|
CF01 | Termination of patent right due to non-payment of annual fee |